An established drug for recurrent multiple myeloma might effectively be repurposed to improve the survival and day-to-day lives of patients with devastating sickle cell disease, according to revealing new research by a Feinstein Institute for Medical Research scientist.
The study, by Lionel Blanc, PhD, an assistant investigator at the Feinstein Institute, will be published Dec. 17 in the journal Blood. Dr. Blanc’s research, performed in collaboration with the New York Blood Center, Yale School of Medicine and University of Montpellier in France, was the first to identify how the drug pomalidomide increases production of fetal hemoglobin, known to interfere with the so-called “sickling” of red blood cells implicated in sickle cell disease (SCD).
Illuminating pomalidomide’s mechanism of action offers proof of concept that the US Food and Drug Administration (FDA)-approved medication could potentially be used to treat SCD, representing better outcomes compared to current drug treatment for the 100,000 Americans with SCD, an inherited disorder causing poor oxygen delivery, organ damage and even death.
“We knew the drug would make fetal hemoglobin, but we didn’t know to what extent or how. That was the goal of the study,” explained Dr. Blanc, also an assistant professor of molecular medicine and pediatrics at Hofstra North Shore-LIJ School of Medicine and an Allied World St. Baldrick’s Scholar.
“We can also say something else – that hydroxyurea, the only FDA-approved drug for sickle cell anemia, was less effective than pomalidomide and appeared to act through a different mechanism of action,” he added. “The current therapy is good, but not everyone responds equally to hydroxyurea, and what we hope with pomalidomide is to improve this.”
Pomalidomide, a derivative of thalidomide used in advanced cases of the cancer multiple myeloma, works by killing malignant plasma cells. But Dr. Blanc and his colleagues demonstrated in the new research, performed on stem cells taken from five SCD patients and 120 normal controls, how pomalidomide also generated fetal hemoglobin, the fetal version of the protein in red blood cells that carries oxygen to body tissues.
In patients with congenital conditions producing anemia such as SCD and beta-thalassemia, fetal hemoglobin is normal, but adult hemoglobin – produced after birth – is abnormal. Therefore, reversing their production of adult hemoglobin back to fetal hemoglobin can reverse the course of their disease.
In addition to the 100,000 US residents with SCD, the condition also affects millions globally. “I would remind people that anemia impacts 1.6 billion people worldwide, making it a global economic burden,” Dr. Blanc notes.
Dr. Blanc and his colleagues in the Division of Hematology/Oncology at Cohen Children’s Medical Center of New York plan to launch a clinical trial in the near future in collaboration with other institutions to test pomalidomide, which is taken orally, in young adults with SCD.
Currently, the only potential cures for SCD are gene therapy, still in the experimental stage, or stem cell transplant, but these resource-intense treatments aren’t available to the vast majority of patients, particularly in the developing world.
“Our hope is to alleviate the symptoms of sickle cell disease by using a pill that could be made available to almost all patients, worldwide,” Dr. Blanc said.
The Latest on: Sickle Cell Disease
via Google News
The Latest on: Sickle Cell Disease
- Nicox’s Partner Fera Pharmaceuticals Files Application for Orphan Drug Designation for Naproxcinod in Sickle-Cell Diseaseon April 1, 2020 at 10:30 pm
Press ReleaseNicox’s Partner Fera Pharmaceuticals Files Application for Orphan Drug Designation for Naproxcinod in Sickle-Cell Disease April 2, ...
- CRISPR therapeutics braces for ‘severe impact’ from COVID-19 crisison April 1, 2020 at 4:43 am
For example, with respect to our CTX001 clinical trials for severe hemoglobinopathies (specifically, transfusion-dependent beta thalassemia and severe sickle cell disease), since [intensive care unit] ...
- What exactly is sickle cell anaemia?on March 31, 2020 at 4:02 pm
The lack of oxygen in the blood can damage nerves and organs including kidneys, the liver and spleen. Sickle cell disease is an inherited blood disorder/condition usually diagnosed at birth. Most ...
- FDA signs off on study of CRISPR drug for sickle cell diseaseon March 31, 2020 at 12:19 pm
(NTLA -2.0%) announces that the FDA has signed off on collaboration partner Novartis' (NVS -0.6%) IND for a Phase 1/2 clinical trial evaluating a CRISPR/Cas9-based engineered cel ...
- ‘It’s the disparity in who gets affected’: A sickle cell doctor tracks dollars and drug developmenton March 31, 2020 at 1:48 am
Sickle cell disease and cystic fibrosis are both rare, genetic diseases. While there are three times as many people (predominantly of African ancestry) in the U.S. with sickle cell disease compared to ...
- Study Finds Funding Disparities Between Sickle Cell Disease, Cystic Fibrosison March 30, 2020 at 2:11 pm
Disparities in funding exist between sickle cell disease (SCD) and cystic fibrosis, according to a study published in JAMA Network Open. For SCD, the disparities may be associated with decreased ...
- Bimbo Akintola, Okey Uzoeshi feature in sickle cell themed film Strainon March 24, 2020 at 5:15 pm
During our research, we made a heart-wrenching discovery that about 150,000 children are still being born with sickle cell disease annually in Nigeria.” Continuing, she says, “At that point, we knew ...
- Sickle Cell theme movie, Strain to be released soonon March 20, 2020 at 9:18 pm
Train, a feature film about a family that suddenly discovers that their young son has the sickle cell disease, will be released later in the year as production is at finishing stage. Speaking at a ...
- Sickle cell and the first African congress on the disorderon March 20, 2020 at 5:00 pm
Tola DehindeRecently, I had the pleasure of meeting two people who are the national and international coordinators of African Congress on Sickle Cell Disease. They told me a lot about what they do and ...
- 2020 Market Spotlight: Sickle Cell Anemia - Key...on March 20, 2020 at 4:48 am
This report covers the sickle cell anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, patent information, ...
via Bing News